VTRS Viatris Inc stock chart & analysis
Conviction 33HealthcareScan · Fri, Nov 6, 2026Viatris Inc (VTRS) closed at $19.91 (+4.96%) on Nov 6, 2026. Price is above its 50-day and above its 200-day moving average. RSI(14) 68, RS Rating 96, at a 52-week high, +60.0% year to date. Sector: Healthcare · Pharmaceutical Preparations.
Financials as of Wed, Sep 30, 2026 · quarterly.
VTRS technical analysis
Trend
VTRS is in an uptrend: price is above the 50-day, which is above the 200-day moving average. It closed 12.5% above the 50-day ($17.70) and 24.1% above the 200-day ($16.05). ADX(14) at 26 points to a strong, established trend. It meets 8 of 8 trend-template criteria.
Momentum
RSI(14) is 68, in the bullish half of its range. The MACD histogram is positive. A bearish RSI divergence is in place. Its RS Rating of 96 puts its weighted 12-month performance ahead of about 96% of the US market, and its RS line is at a new high.
Volume and volatility
Volume on the latest session ran 1.9× its 20-day average. It trades about $168.9M a day on average. ATR(14) is $0.5702, 2.9% of price — its typical daily range. On-balance volume is trending up. Chaikin Money Flow (0.08) shows accumulation.
Key levels
The chart pattern's support is $16.88 and its resistance $19.13. The 52-week range is $9.92 to $19.96, and price sits at the high. The VWAP anchored at the 52-week high is $19.43, below price.
Performance
VTRS returned +4.7% (1 week), +14.2% (1 month), +22.4% (3 months), +16.0% (6 months), +85.3% (1 year), +60.0% (year to date).
About Viatris Inc
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
Pharmaceutical Preparations · Listed 1973 · 30,000 employees
Recent news
- Viatris Inc: Ownership stake amendedSEC EDGAR · Fri, Nov 6, 2026
- Viatris Announces Quarterly DividendPR Newswire · Wed, Nov 4, 2026
Congress activity
Disclosed STOCK Act trades in VTRS · 3 recent
Insider activity
SEC Form 4 transactions in VTRS · open-market 1 sell
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Enrietti Andrew See Remarks · Common Stock · 2026-08-15 | Exercise | 25.13K | — | 2026-08-15 | 2026-08-18 |
Enrietti Andrew See Remarks · Common Stock · 2026-08-15 | Tax | 10.93K | $177K | 2026-08-15 | 2026-08-18 |
Enrietti Andrew See Remarks · Common Stock · 2026-08-15 | Exercise | 999 | — | 2026-08-15 | 2026-08-18 |
Enrietti Andrew See Remarks · Common Stock · 2026-08-15 | Tax | 435 | $7K | 2026-08-15 | 2026-08-18 |
Enrietti Andrew See Remarks · Restricted Stock Units · 2026-08-15 | Exercise | 25.13K | — | 2026-08-15 | 2026-08-18 |
Enrietti Andrew See Remarks · Dividend Equivalent Units · 2026-08-15 | Exercise | 998.364 | — | 2026-08-15 | 2026-08-18 |
Campbell Paul See Remarks · Common Stock · 2026-06-25 | Sell | 50.08K | $810K | 2026-06-25 | 2026-06-26 |
Le Goff Corinne Chief Commercial Officer · Common Stock · 2026-04-15 | Tax | 17.45K | $242K | 2026-04-15 | 2026-04-16 |
Le Goff Corinne Chief Commercial Officer · Common Stock · 2026-04-15 | Exercise | 39.34K | $0 | 2026-04-15 | 2026-04-16 |
Le Goff Corinne Chief Commercial Officer · Common Stock · 2026-04-15 | Exercise | 3.64K | $0 | 2026-04-15 | 2026-04-16 |
SEC filings
EDGAR filings in VTRS · 10 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.
Start free — 7-day trial, no card →Free daily signals by email. Top 3 setups per lane after every close. No account needed.
Unsubscribe anytime · Privacy
Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.